## Yuto Matsushita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6300245/publications.pdf

Version: 2024-02-01

49 383 11 papers citations h-index

51 51 51 441 all docs docs citations times ranked citing authors

16

g-index

#	Article	IF	CITATIONS
1	Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis. BJU International, 2022, 130, 226-234.	2.5	15
2	Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 107.e1-107.e9.	1.6	1
3	Initial experience of robotâ€assisted radical nephrectomy in Japan: Single institutional study of 12 cases. Asian Journal of Endoscopic Surgery, 2022, 15, 162-167.	0.9	3
4	Feasibility of interaortocaval clamping for renal artery during robotâ€assisted right partial nephrectomy: A propensity scoreâ€matching analysis. Asian Journal of Endoscopic Surgery, 2022, , .	0.9	0
5	Limited impact of erectile function on healthâ€related quality of life in Japanese men undergoing robotâ€assisted radical prostatectomy. International Journal of Urology, 2022, 29, 956-961.	1.0	4
6	Bladder cancer prospective cohort study on highâ€risk nonâ€muscle invasive bladder cancer after photodynamic diagnosisâ€assisted transurethral resection of the bladder tumor (BRIGHT study). International Journal of Urology, 2022, 29, 632-638.	1.0	10
7	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2022, , .	1.3	O
8	Pembrolizumab <i>Versus</i> Combined Chemotherapy With Gemcitabine and Paclitaxel: A Comparative Assessment of Clinical Outcomes in Patients With Platinum-refractory Advanced Urothelial Cancer. In Vivo, 2021, 35, 1889-1894.	1.3	4
9	Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study. BMC Cancer, 2021, 21, 266.	2.6	18
10	Mass spectrometric profiling of DNA adducts in the human stomach associated with damage from environmental factors. Genes and Environment, 2021, 43, 12.	2.1	11
11	Health-Related Quality of Life in Patients with Small Renal Mass Who Underwent Robot-Assisted Partial Nephrectomy: A Prospective Evaluation. Journal of Endourology, 2021, 35, 1644-1649.	2.1	4
12	Geospatial Assessments of DNA Adducts in the Human Stomach: A Model of Field Cancerization. Cancers, 2021, 13, 3728.	3.7	3
13	Prognostic assessments in patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy and systematic regional lymph node dissection. Urologia, 2021, , 039156032110349.	0.7	1
14	Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents. International Journal of Clinical Oncology, 2021, 26, 1745-1751.	2.2	6
15	Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells. Anticancer Research, 2021, 41, 3753-3758.	1.1	2
16	Impact of Bladder Neck Angle Measured by Postoperative Magnetic Resonance Imaging on Midterm Recovery of Urinary Continence in Prostate Cancer Patients Undergoing Robot-Assisted Radical Prostatectomy. Journal of Endourology, 2021, 35, 1610-1615.	2.1	1
17	Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Science, 2021, 112, 760-773.	3.9	49
18	Significance of 5-Aminolevulinic Acid-mediated Photodynamic Diagnosis Following Standard Transurethral Resection in Non-muscle Invasive Bladder Cancer. Cancer Diagnosis & Prognosis, 2021, 1, 201-205.	0.7	1

#	Article	IF	CITATIONS
19	A DNA adductome analysis revealed a reduction in the global level of C5-hydroxymethyl-2′-deoxycytidine in the non-tumoral upper urinary tract mucosa of urothelial carcinoma patients. Genes and Environment, 2021, 43, 52.	2.1	4
20	Initial learning curve for robotâ€assisted partial nephrectomy performed by a single experienced robotic surgeon. Asian Journal of Endoscopic Surgery, 2020, 13, 59-64.	0.9	14
21	Improved perioperative outcomes by early unclamping prior to renorrhaphy compared with conventional clamping during robot-assisted partial nephrectomy: a propensity score matching analysis. Journal of Robotic Surgery, 2020, 14, 47-53.	1.8	13
22	Feasibility of the ACL (albumin, C-reactive protein and lactate dehydrogenase) model as a novel prognostic tool in patients with metastatic renal cell carcinoma previously receiving first-line targeted therapy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 6.e9-6.e16.	1.6	9
23	Predictive factors for persistence of preoperative overactive bladder symptoms after transvaginal mesh surgery in women with pelvic organ prolapse. LUTS: Lower Urinary Tract Symptoms, 2020, 12, 167-172.	1.3	4
24	Perioperative outcomes in patients undergoing robotâ€assisted partial nephrectomy: Comparative assessments between complex and nonâ€complex renal tumors. Asian Journal of Endoscopic Surgery, 2020, 14, 379-385.	0.9	3
25	Kidney transplantation from a living donor with renal artery fibromuscular dysplasia: A case report on arterial grafting of the donor renal artery. IJU Case Reports, 2020, 3, 201-203.	0.3	3
26	Enhanced Sensitivity to NVP-BEZ235 by Inhibition of p62/SQSTM1 in Human Bladder Cancer KoTCC-1 Cells Both In Vitro and In Vivo. In Vivo, 2020, 34, 1001-1008.	1.3	3
27	Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer. Anticancer Research, 2020, 40, 1101-1106.	1.1	3
28	Second transurethral resection for high-risk non-muscle invasive bladder cancer patients: a propensity score matched analysis. Japanese Journal of Clinical Oncology, 2020, 50, 718-721.	1.3	2
29	Corticosteroids alleviate adverse events associated with enzalutamide in patients with metastatic castrationâ€′resistant prostate cancer. Molecular and Clinical Oncology, 2020, 12, 495-500.	1.0	1
30	Comprehensive assessment of oncological outcomes in 186 patients with high‑risk non‑muscle‑invasive bladder cancer: A single institution retrospective study. Molecular and Clinical Oncology, 2020, 13, 16.	1.0	1
31	Robot-Assisted Partial Nephrectomy for Patients with Multifocal Renal Tumors Arising in a Solitary Kidney: Report of Three Cases. Journal of Endourology Case Reports, 2020, 6, 370-373.	0.3	1
32	Clinical characteristics of selfâ€reported nocturia in patients with interstitial cystitis, and effects of bladder hydrodistention (with fulguration of Hunner lesions) on nocturia. LUTS: Lower Urinary Tract Symptoms, 2019, 11, 0141-0146.	1.3	4
33	Early Single-Center Experience with Robotic Partial Nephrectomy Using the da Vinci Xi: Comparative Assessment with Conventional Open Partial Nephrectomy. Current Urology, 2019, 13, 13-18.	0.6	12
34	Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy. Anticancer Research, 2019, 39, 1067-1072.	1.1	3
35	Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer. Anticancer Research, 2019, 39, 1391-1396.	1.1	38
36	Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology, 2019, 24, 842-847.	2.2	8

#	Article	IF	CITATIONS
37	Significant impact of three-dimensional volumetry of perinephric fat on the console time during robot-assisted partial nephrectomy. BMC Urology, 2019, 19, 132.	1.4	9
38	Marked response to nivolumab combined with external radiation therapy for metastatic renal cell carcinoma: report of two cases. International Cancer Conference Journal, 2019, 8, 29-32.	0.5	10
39	Therapeutic Endoscopic Treatment Plus Maintenance Dimethyl Sulfoxide Therapy Prolongs Recurrence-Free Time in Patients With Hunner Type Interstitial Cystitis: A Pilot Study. International Neurourology Journal, 2019, 23, 327-333.	1.2	3
40	Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus. International Journal of Clinical Oncology, 2018, 23, 553-558.	2.2	14
41	No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology, 2018, 23, 576-583.	2.2	4
42	Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan. Clinical Genitourinary Cancer, 2018, 16, 219-225.	1.9	17
43	Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years. Anticancer Research, 2018, 38, 3593-3599.	1.1	4
44	Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel. Anticancer Research, 2018, 38, 4179-4185.	1.1	19
45	Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma. Medical Oncology, 2018, 35, 133.	2.5	15
46	Systematic regional lymph node dissection for upper tract urothelial carcinoma improves patient survival. Japanese Journal of Clinical Oncology, 2017, 47, 239-246.	1.3	8
47	Contralateral pneumothorax during retroperitoneal laparoscopic donor nephrectomy: A case report. Asian Journal of Endoscopic Surgery, 2017, 10, 202-204.	0.9	4
48	No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer. Medical Oncology, 2017, 34, 141.	2.5	9
49	Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide. Medical Oncology, 2017, 34, 200.	2.5	7